Extract
Non-tuberculous mycobacteria (NTM) are an emerging pathogen worldwide in both cystic fibrosis (CF) and non-CF pulmonary disease (PD), with reports suggesting an increasing prevalence [1, 2]. It is an opportunistic infection acquired from the environment [3], though conflicting evidence remains around person-to-person transmission [4, 5]. Recent evidence suggests that Mycobacterium abscessus complex (MABSC) may be the most detrimental airway infection to lung function in CF [6] yet its treatment remains poorly evidenced.
Footnotes
This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.
Conflict of interest: Dr. Kohli has nothing to disclose.
Conflict of interest: Dr. Hughes has nothing to disclose.
Conflict of interest: Dr. Bokobza has nothing to disclose.
Conflict of interest: Dr. Carr reports personal fees and other from Chiesi Pharmaceuticals, non-financial support and other from Vertex, other from Zambon, other from Insmed, outside the submitted work;.
- Received September 25, 2020.
- Accepted January 28, 2021.
- ©The authors 2021. For reproduction rights and permissions contact permissions{at}ersnet.org
LIBRARY USERS
Log in through your institution
Purchase access
